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httpcense.Abstract Introduction: The risk of ventilator-associated pneumonia (VAP) is highest early in the
course of hospital stay. Most clinicians continue to rely on a clinical diagnosis of hospital-acquired
pneumonia (HAP) because it is convenient. In an effort to improve the speciﬁcity of clinical diag-
nosis, the clinical pulmonary infection score (CPIS) was developed. Serum C-reactive protein (CRP)
measurements in intensive care unit (ICU) patients enabled the early diagnosis of sepsis.
Aim of the work: The aim of this work was to evaluate the role of the clinical pulmonary infec-
tion score and C-reactive protein in the prediction of early ventilator associated pneumonia.
Patients and methods: Eighty patients recently were intubated and mechanically ventilated with
no manifestations of infection; no inﬁltrates on chest X-ray for 48 h after intubation and had nor-
mal serum CRP at the ﬁrst day of intubation. All patients were admitted to the intensive care unit in
the Chest Department, Alexandria University Hospital and enrolled after obtaining informed con-
sents. All patients were subjected to the following: full history taking, thorough clinical examina-
tion, laboratory investigations including total and differential white blood count, radiological
evaluation, daily serum CRP assessment during the ﬁrst 5 days of intubation and the calculation
of CPIS at the onset of rising CRP.
Results: In this study, the age of all patients ranged from 34 years to 65 years with a mean age of
50.1 ± 8.7 years. There were 44 male patients representing (55%) and 36 female patients represent-
ing (45%) of the study population. Serum CRP ranged from 0.8 to 3 mg/l with a mean of
1.1 ± 0.4 mg/l on the ﬁrst day of intubation and from 3.1 to 5 mg/l with a mean of
4.2 ± 0.4 mg/l on the second day of intubation for all patients. On the third day of intubation,24474317.
hoo.com (E.E. Mohamed),
in Ali Abd Alla).
he Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
://dx.doi.org/10.1016/j.ejcdt.2013.07.015
454 E.E. Mohamed, A.El.D.A. Abd Allaserum CRP ranged from 18 to 38 mg/l with a mean of 27.0 ± 4.7 mg/l in 11 patients while on the
fourth day of intubation serum CRP ranged from 32 to 59 mg/l with a mean of 46.2 ± 6.9 mg/l in
12 patients. Lastly, serum CRP ranged from 50 to 66 mg/l with a mean of 60.7 ± 2.6 mg/l on the
ﬁfth day of intubation in 9 patients. Therefore, serum CRP increased in 32 patients. CPIS of the
studied patients at the onset of rising serum CRP ranged from 7 to 10 in 24 patients. In the ﬁrst
5 days of intubation, 32 patients out of 80 patients had high CRP, those were 40% of the study pop-
ulation and 24 patients of those 32 patients had high CPIS; those were 30% of the study population
and 75% of patients had high CRP.
Conclusion: When the CPIS exceeded 6, there was an association with the presence of pneumo-
nia which was conﬁrmed by microbiological culture furthermore serum CRP is an easy, available
and cheap test so daily serum CRP measurements to ICU patients enabled the early diagnosis of
pneumonia and enhanced the value of the CPIS. Further studies of CPIS are needed with particular
attention to how its variability might affect therapeutic choices.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Ventilator associated pneumonia (VAP) is an important form
of hospital acquired pneumonia (HAP), speciﬁcally developing
in a mechanically ventilated patient more than 48 h after tra-
cheal intubation [1]. The overall or crude mortality associated
with VAP ranges from 40% to 70% varying with underlying
illness, the etiologic pathogen of lung infection, associated bac-
teremia, and the adequacy of the empiric antibiotic treatment
[2–4]. However, the real impact of VAP is difﬁcult to ascertain
because risk factors for pneumonia such as underlying disease
or the severity of illness also predispose patients to a greater
mortality, and therefore these are potentially confounding
variables. Therefore, whether patients die of or only with nos-
ocomial pneumonia is probably one of the most difﬁcult ques-
tions to answer [3].
Most clinicians continue to rely on a clinical diagnosis of
HAP because it is convenient. The presence of pneumonia is
deﬁned by new lung inﬁltrate plus clinical evidence that the
inﬁltrate is of an infectious origin. The presence of a new or
progressive radiographic inﬁltrate plus at least two of three
clinical features (fever greater than 38 C, leucocytosis or leu-
copenia, and purulent secretions) represents the most accurate
combination of criteria for starting empiric antibiotic therapy.
Requiring all three clinical criteria is too insensitive and it will
result in many patients with true pneumonia not receiving
therapy [5].
In an effort to improve the speciﬁcity of clinical diagnosis,
Pugin et al. developed the clinical pulmonary infection score
(CPIS) [6]. In addition, it improved if a Gram stain of a deep
respiratory tract culture was added to the evaluation (Table 1)
[7]. When the CPIS exceeded 6, good correlation with the pres-
ence of pneumonia, as deﬁned by quantitative cultures of
bronchoscopic and non bronchoscopic BAL specimens, was
found [8].
One prospective study evaluated 79 episodes of suspected
VAP using the CPIS, and compared the ﬁndings with diagnosis
established by BAL culture. A persistently low score <6 for
3 days in patients with suspected nosocomial pneumonia makes
the diagnosis unlikely and might guide the decision to stop
treatment with antibiotics [6]. The original description of the
CPIS required microbiologic data, and thus could not be used
to screen for HAP. Singh et al. used a modiﬁed CPIS that did
not rely on culture data to guide clinical management [9].If a clinical strategy is used, reevaluation of the decision to
use antibiotics based on serial clinical evaluations, by day 3 or
sooner, is necessary, because patients who are improving will
have signs of good clinical response by this time point [10].
Singh et al. have shown that some patients with a low clinical
suspicion of VAP (CPIS of 6 or less) can have antibiotics safely
discontinued after 3 days, if the subsequent course suggests
that the probability of pneumonia is still low. This modiﬁed
CPIS used by Singh et al. appears to be an objective measure
to deﬁne patients who can receive a short duration of therapy
[9].
C-reactive protein (CRP) is a plasma protein; an acute
phase protein produced by the liver and adipocytes. It was
originally discovered by Tillett and Francis in 1930 as a sub-
stance in the serum of patients with acute inﬂammation that
reacted with the C-polysaccharide of pneumococcus. Initially
it was thought that CRP might be a pathogenic secretion, as
it was elevated in people with a variety of illnesses, including
carcinomas. Discovery of hepatic synthesis and secretion of
CRP closed that debate. It is thought to bind to phosphocho-
line, thus initiating recognition and phagocytosis of damaged
cells [11].
CRP is a member of the class of acute phase reactants as
its levels rise dramatically during inﬂammatory processes
occurring in the body. This increment is due to a rise in
the plasma concentration of IL-6 which is produced by mac-
rophages, endothelial cells and T-cells as well as adipocytes.
CRP binds to phosphorylcholine on microbes. It is thought
to assist in complement binding to foreign and damaged
cells and enhances phagocytosis by macrophages, which ex-
press a receptor for CRP. It is also believed to play an
important role in innate immunity, as an early defense sys-
tem against infections. The health care provider might use
the CRP test to check for ﬂare-ups of inﬂammatory diseases
like rheumatoid arthritis, lupus, or vasculitis. The test might
also be used to tell if anti-inﬂammatory medicine is working
[12].Aim of the work
The aim of this work was to evaluate the role of the clinical
pulmonary infection score and C-reactive protein in the predic-
tion of early ventilator associated pneumonia.
Table 3 Clinical pulmonary infection score (CPIS) of the
studied patients at the onset of rising CRP.
Temperature (C) 38–40
39.04 ± 0.680
At onset of VAP (WBCs (/mm3)) 12–23
16.62 ± 2.486
Bronchoalveolar lavage (BAL) Gram stain (number of patients)
Gram negative 17
Gram positive 7
Secretions (number of patients)
Table 1 The clinical pulmonary infection score (CPIS) [7].
Temperature P36.5 6 38.4 0
P38.4 6 38.9 1
<36 or P39 2
White blood count P4000 6 11,000 0
<4000 or >11,000 1
Secretions 6small/day 0
Moderate/large 1
Purulent 2
Chest radiograph No inﬁltrate 0
Diﬀuse/patchy inﬁltrate 1
Localized inﬁltrate 2
PaO2/FiO2 ratio >240 without ARDS 0
<240 without ARDS 2
Culture <10,000 bacteria or no growth 0
>10,000 bacteria 1
Positive Gram stain 1 Table 2 The age, sex, duration of ICU stay and CRP of the
studied patients.
Age(years) 34–65
50.1 ± 8.7
Sex
Male 44(55%)
Female 36(45%)
Duration of Stay in ICU(days) 18–38
27.1 ± 4.7
CRP (mg/l)
1st day (in the 80 patients) 0.8–3
1.1 ± 0.4
2rd day (in the 80 patients) 3.1-5
4.2 ± 0.4
3th day (in 11 patients) 18–38
27.0 ± 4.7
4th day (in 12 patients) 32–59
46.2 ± 6.9
5th day (in 9 patients) 50–66
60.7 ± 2.6
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Study population and subjects
Eighty patients recently were intubated and mechanically venti-
lated with no manifestations of infection; no inﬁltrates on chest
X-ray for 48 h after intubation and had normal serum CRP at
the ﬁrst day of intubation. All patients were admitted to the
intensive care unit in the Chest Department, Alexandria Univer-
sity Hospital and enrolled after obtaining informed consents.
Study measurements
All patients were subjected to the following:
 Full history taking including age, sex and history of other
diseases.
 Thorough clinical examination including: general examina-
tion and local chest examination.
 Daily Laboratory investigations including total and differ-
ential white blood cells.
 Daily Radiological evaluation for new pulmonary inﬁltrates
was carried out by:
 Plain X-ray chest postero-anterior and lateral views.
 Serum C-reactive protein (CRP) assessment daily during
the ﬁrst 5 days of intubation.
 Calculation of the clinical pulmonary infection score (CPIS)
at the onset of rising CRP.
 Broncho-alveolar lavage (BAL) at the onset of rising CRP.
6Small/day 3
Moderate to large 16
Purulent 5
Chest radiograph (number of patients)
No inﬁltrate 4
Diﬀuse/patchy inﬁltrate 6
Localized inﬁltrate 14
PaO2/FiO2 ratio (number of patients)
<240 without ARDS 16
>240 without ARDS 8
CPIS (in 24 patients) 7–10
8.48 ± 1.031Statistical analysis
Statistical analysis will be performed with Sigma Stat 2.0 (Sy-
stat Software Inc., Point Richmond, Calif) and SPSS 14 (SPSS,
Chicago, Ill) for Windows.
Results
In this study, eighty patients were mechanically ventilated with
no manifestations of infection and had normal serum CRP atthe ﬁrst day of intubation. The age of all patients ranged from
34 to 65 years with the mean age of 50.1 ± 8.7 years. There
were 44 male patients representing (55%) and 36 female pa-
tients representing (45%) of the study population. The dura-
tion of stay in the ICU ranged from 18 to 38 days with the
mean duration of 27.1 ± 4.7 days. Serum CRP was measured
for all patients. Serum CRP ranged from 0.8 to 3 mg/l with the
mean of 1.1 ± 0.4 mg/l at the ﬁrst day of intubation and from
3.1 to 5 mg/l with the mean of 4.2 ± 0.4 mg/l at the second day
of intubation for all patients. At the third day of intubation,
serum CRP ranged from 18 to 38 mg/l with the mean of
27.0 ± 4.7 mg/l in 11 patients while at the fourth day of intu-
bation serum CRP ranged from 32 to 59 mg/l with the mean of
46.2 ± 6.9 mg/l in 12 patients. Lastly, serum CRP ranged from
50 to 66 mg/l with the mean of 60.7 ± 2.6 mg/l at the ﬁfth day
Table 4 CRP and CPIS.
Day 1 Day 2 Day 3 Day 4 Day 5
Positive CRP (n= 32/80) 40% of all patients (n= 0/80) (n= 0/80) (n= 11/80) (n= 12/80) (n= 9/80)
High CPIS (n= 24/32) 75% of CRP +ve patients 30% of all patients – – (n= 8/11) (n= 10/12) (n= 6/9)
0 
2 
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14
Day 1 Day 2 Day 3 Day 4 Day 5
CRP CPIS 
Figure 1 Number of patients with positive CRP and high CPIS.
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creased in 32 patients.
Clinical Pulmonary Infection Score (CPIS) of the studied
patients at the onset of rising CRP ranged from 7 to 10 (Ta-
ble 3) in 24 patients.
At the ﬁrst and second day of intubation, serum CRP was
normal for all the eighty patients. At the third day of intuba-
tion serum CRP increased in 11 patients, 8 of them had high
CPIS (ranged from 7 to 10) at the onset of rising serum
CRP. At the fourth day of intubation serum CRP increased
in 12 patients, 10 of them had high CPIS (ranged from 7 to
10) at the onset of rising serum CRP. At the ﬁfth day of intu-
bation serum CRP increased in 9 patients, 6 of them had high
CPIS (ranged from 7 to 10) at the onset of rising serum CRP
(Table 4).
Therefore in the ﬁrst 5 days of intubation, 32 patients out of
80 patients had high serum CRP, those were 40% of the study
population and 24 patients of those 32 patients had high CPIS;
those were 30% of the study population and 75% of patients
with high serum CRP (Fig. 1).
Microbiological evaluation of the bronchoalveolar lavage
(BAL) of the studied patients (Table 5) showed that, fungalTable 5 Bronchoalveolar lavage (BAL) of the studied
patients.
Bronchoalveolar lavage (BAL) (fungi)
Candida 8
Negative 16
Bronchoalveolar lavage (BAL) (microorganism)
Klebsiella pneumonia 7(29.17%)
MRSA 4(16.67%)
Pseudomonas aeruginosa 10(41.66%)
Streptococcus pneumoniae 3(12.5%)infection was found in 8 patients in association with other
microorganisms. The most common organism was Pseudomo-
nas aeruginosa (10 patients), followed by Klebsiella pneumonia
(7 patients) then methicillin resistant Staphylococcus aureus
(MRSA) (4 patients) and ﬁnally Streptococcus pneumoniae (3
patients). So positive microbiological cultures were found the
24 patients with high CPIS.
Discussion
The single greatest risk factor for VAP is related to the dura-
tion of mechanical ventilation. Early VAP occurs within the
ﬁrst 5 days of intubation. Late-onset VAP occurs after 5 days,
is more commonly caused by multidrug resistant (MDR)
pathogens, and carries higher morbidity and mortality [7,8].
The risk peaks at day 5 on the ventilator, plateaus after day
15, and then declines signiﬁcantly, with the result that VAP
is uncommon in patients on long-term mechanical ventilation
[13]. The risk of VAP is highest early in the course of hospital
stay, and is estimated to be three percent per day during the
ﬁrst ﬁve days of ventilation, two percent per day during days
5 to 10 of ventilation, and one percent per day after this [14].
In this study, all patients were assessed and they had nor-
mal serum CRP in the ﬁrst and second day of intubation.
Starting from the third to the ﬁfth day of intubation, 32 pa-
tients out of 80 patients had high serum CRP, those were
40% of the study population and 24 patients of those 32 pa-
tients had high CPIS; those were 30% of the study population
and 75% of patients with high serum CRP.
Smith et al. [15] used CRP as a useful sensitive marker of
bacterial infection in cases of pneumonia. There was marked
elevation of serum level of CRP within a few hours of
infection.
CRP test is considered as a general test, not a speciﬁc one.
In other words, it can reveal that there is inﬂammation present
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many conditions like urinary tract infection, bacterial meningi-
tis, pelvic inﬂammatory disease (PID), whole-body infection
(sepsis), appendicitis, polymyalgia rheumatic, inﬂammatory
bowel disease, temporal arteritis, rheumatoid arthritis, lupus,
gout, Reiter’s syndrome, Crohn’s disease, acute pancreatitis,
Hodgkin’s lymphoma, tuberculosis and burns. A special type
of CRP test, the high-sensitivity CRP test (hs-CRP), may be
done to evaluate the risk for having a sudden heart problem,
such as a heart attack. However, the connection between high
CRP levels and heart attack risk is not yet fully known [16].
Nonetheless, observations made in several studies suggested
the usefulness of CRP to diagnose VAP. Povoa et al. [17]
found that, for a threshold of 9.6 mg/l, CRP had 87% sensitiv-
ity and 88% speciﬁcity for VAP diagnosis. These same investi-
gators also reported that daily CRP measurements in ICU
patients enabled the early diagnosis of sepsis [18].
The investigators of numerous studies concluded that CRP
contributes to diagnosing invasive bacterial infection, implying
that it might have a role in the emergency department or ICU.
However, CRP use for diagnostic purposes has yielded widely
conﬂicting data. Some argue that because CRP is, by deﬁni-
tion, a nonspeciﬁc indicator of inﬂammation, it cannot accu-
rately differentiate among the many sources of potential
tissue destruction [19–22].
In the present study, CPIS ranged from 7 to 10 in 24-pa-
tients from 32-patients at the onset of rising CRP, they repre-
sented (75%) of patients with high serum CRP and early
microbiological evaluation of a deep respiratory tract culture
was done at the onset of rising CRP. The most common organ-
ism was P. aeruginosa followed by Klebsiella pneumonia then
MRSA and S. pneumoniae in the 24 patients with high CPIS.
Because there are other potential causes of fever, leukocyto-
sis, and pulmonary inﬁltrates, clinical diagnostic criteria are
overly sensitive in the diagnosis of VAP. So the CPIS combines
clinical, radiographic, physiological (PaO2/FiO2), and microbi-
ologic data into a single numerical result. In recent years, the
CPIS has been used both for the early diagnosis of VAP and
as a clinical indicator of the outcome of the infection [23].
Schurink et al. [24] found that ventilator-associated pneu-
monia was diagnosed in (69.6%) of patients. When using a
CPIS >5 as diagnostic cutoff, the sensitivity of the score
was 83%. Although quantitative microbiological cultures of
samples obtained by bronchoscopy are considered the most
speciﬁc tool for diagnosing ventilator-associated pneumonia,
this labor-intensive invasive technique is not widely used.
Alternative infectious sources, such as urinary tract, skin
and soft-tissue infections, and device-related infections (i.e.,
central venous catheters) are common in hospitalized patients
and should be ruled out before diagnosing VAP [25]. This is
why in this study 25% of patients with high CRP levels had
a CPIS of less than 6 and no evidence of VAP.
Chastre et al. [26] used the CPIS for the early diagnosis of
pneumonia in patients at higher risk to have VAP. In a retro-
spective study involving 58 patients with severe brain injuries,
Pelosi et al. [27] found the CPIS to increase from ICU entry to
the day of VAP onset, providing 97% sensitivity and 100%
speciﬁcity for the VAP diagnosis.
Papazian et al. [28] used the CPIS in a prospective post-
mortem study of 38 patients who died after 72 h of mechanical
ventilation; 18 of these patients had histological evidence of
pneumonia. The strength of this analysis was that histologicexamination of tissue samples served as the gold standard
for diagnosis. The authors’ ﬁndings indicated that, at the
threshold of 6 points, the CPIS achieved a sensitivity of
72%, a speciﬁcity of 85%, and an overall accuracy of 79%
for the presence of VAP; combining it with quantitative culture
resulted in a slight increase in speciﬁcity (95%) at the expense
of diminished sensitivity (67%).
One limitation of the earlier studies attempting to validate
the CPIS is that none examined the CPIS in selected cohorts
of patients for whom the diagnosis of VAP may have been par-
ticularly challenging. For example, in patients with acute lung
injury, it is often difﬁcult to determine whether a radiograph
shows a new or changing inﬁltrate. Unfortunately, no studies
have speciﬁcally addressed the CPIS in persons with acute
respiratory distress syndrome, despite the fact that these per-
sons are at exceedingly high risk of VAP. Moreover, few stud-
ies have explored the CPIS in non-medical populations. This is
of particular concern because surgical patients account for
more than one-half of cases of VAP in the United States
and, in trauma, blunt chest trauma and pulmonary contusion
can mimic the signs and ﬁndings related to VAP.
Emphasizing this point, Croce et al. [29] evaluated the use
of CPIS in critically injured patients. In this retrospective
study, the investigators reviewed 158 polytrauma patients
who had 285 cultures of BAL ﬂuid specimens performed be-
cause of a clinical suspicion of VAP. The prevalence of VAP
with the use of quantitative BAL culture was 42%, with the
remainder representing inﬂammatory changes. The sensitivity
of a CPIS was only 61%, and its speciﬁcity for VAP was only
43%. In addition, there was no pattern to the over- or under-
diagnosis of VAP based on the CPIS in trauma patients. In pa-
tients with a low CPIS, VAP was often found, and many pa-
tients with a high CPIS had negative quantitative culture
results. The authors concluded that, in a trauma population,
the CPIS is not an adequate means for differentiating VAP
from noninfectious causes of lung injury.
Pham et al. [30] reached a similar conclusion in their assess-
ment of CPIS in the treatment of burn patients. These investi-
gators retrospectively calculated the CPIS for 28 patients who
had 46 quantitative cultures performed to diagnose VAP and
tested the characteristics of a CPIS threshold of 6 for the diag-
nosis of VAP. They found that the CPIS had poor discrimina-
tion; patients with positive and negative culture results had a
similar CPIS (the mean CPIS was 5.7 and 5.5, respectively),
and the sensitivity and speciﬁcity of the CPIS was 30% and
80%, respectively.
Early-onset VAP, usually carry a better prognosis, and are
more likely to be caused by antibiotic-sensitive bacteria. How-
ever, patients with early-onset HAP who have received prior
antibiotics or who have had prior hospitalization within the
past 90 days are at greater risk for colonization and infection
with MDR pathogens and should be treated similar to patients
with late-onset VAP [8]. Ventilator-associated pneumonia is an
important cause of morbidity and mortality in critically ill pa-
tients. Evidence-based clinical practice guidelines for the pre-
vention, diagnosis, and treatment of ventilator-associated
pneumonia may improve outcomes [31].
Of all the components of the CPIS, the measure of oxygen-
ation provides the most information as a time-dependent
factor during early VAP for predicting its outcome in response
to treatment, and deriving a complex score appears to be
superﬂuous for this purpose. The CPIS has been most
458 E.E. Mohamed, A.El.D.A. Abd Allasuccessfully used in guiding treatment decisions for patients
with a low likelihood of VAP, for whom CPIS-guided therapy
has resulted in lower costs and reduced the development of
antimicrobial resistance [8].
In conclusion, when the CPIS exceeded 6, there was an
association with the presence of pneumonia which was con-
ﬁrmed by microbiological culture furthermore serum CRP is
an easy, available and cheap test so daily serum CRP measure-
ments to ICU patients enabled the early diagnosis of pneumo-
nia and enhanced the value of the CPIS. Further studies of
CPIS are needed with particular attention to how its variability
might affect therapeutic choices.Conﬂict of interest
None declared.
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